IMMUNOLOGY2026™ Conference Recordings For Attendees-T6B-mediated inhibition of the miRISC decreases myeloid-derived suppressor cell abundance and enhances survival in a murine ovarian cancer model

T6B-mediated inhibition of the miRISC decreases myeloid-derived suppressor cell abundance and enhances survival in a murine ovarian cancer model

Back to course

Video Transcription

Video Summary

Josh Imperatore described research on T6B, a peptide that disrupts the RNA-induced silencing complex (RISC) by blocking TNRC6-Argonaute binding in murine ovarian cancer cells. In doxycycline-inducible MFTC-beta cells, T6B altered gene expression, increased translation-related genes, and improved survival in mice. It shifted the tumor microenvironment toward a less inflammatory state, increasing dendritic cells and macrophages while reducing granulocytic/Ly6G+ cells. T6B also lowered cytokines and tumor-progression genes linked to inflammation and immunosuppression. Future work will examine the mechanism and combine T6B with chemotherapy.

Meta Tag

Date April 19, 2026 8:15 AM - 8:30 AM

Room 156

Session Immune Cells in the Tumor Microenvironment II

Speaker Joshua Imperatore

Track Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

Year 2026

Keywords

T6B peptide

RNA-induced silencing complex

TNRC6-Argonaute binding

ovarian cancer

tumor microenvironment

April 19, 2026 8:15 AM - 8:30 AM

156

Immune Cells in the Tumor Microenvironment II

Joshua Imperatore

Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

2026